+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report by Product (Highly Potent API, Antibody Drug Conjugate), by Synthesis, by Drugs, by Application, by Workflow, by Region, and Segment Forecasts, 2021-2028

  • ID: 5390533
  • Report
  • June 2021
  • Region: Global
  • 100 Pages
  • Grand View Research

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Cambrex
  • Catalent
  • Corden Pharma.
  • Lonza
  • Piramal Pharma Solutions
The global active pharmaceutical ingredients CDMO market size is expected to reach USD 136.1 billion by 2028. The market is expected to expand at a CAGR of 6.7% from 2021 to 2028. Increasing pharmaceutical R&D investment, patent expirations, and rise in demand for generic drugs and biologic innovation are the factors driving the market.





The growth of small molecules, rising Active Pharmaceutical Ingredient (API) complexity, and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the Contract Development and Manufacturing Organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

However, due to the COVID-19 pandemic, governments worldwide have opted to boycott APIs made in China. Due to government-imposed lockdown limitations in China, 44 firms were declared non-operational during the pandemic. As a consequence, various countries have launched programs to develop their own APIs, and countries across the EU have re-evaluated their healthcare models in order to combat the virus and ensure a steady supply of APIs.

COVID-19 has placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving better able to withstand the pressures of quick scale up than others.

Active Pharmaceutical Ingredients CDMO Market Report Highlights

  • The traditional active pharmaceutical ingredient dominated the market and accounted for the largest revenue share of 40.5% in 2020
  • The innovative drugs segment held 74.6% of the revenue share in 2020. This is largely attributed due to increasing FDA approvals for new molecular entities, and the increased focus on R&D by innovator API companies
  • The oncology segment dominated the market and accounted for the largest revenue share of 35.1% in 2020. This is due to the increasing demand for highly active APIs for cancer therapy
  • In Asia Pacific, the market is expected to register the fastest growth rate of 8.9% over the forecast period. Due to the extreme rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Active Pharmaceutical Ingredients CDMO Market

What is the estimated value of the Active Pharmaceutical Ingredients CDMO Market?

The Active Pharmaceutical Ingredients CDMO Market was estimated to be valued at $86.6 billion in 2021.

What is the growth rate of the Active Pharmaceutical Ingredients CDMO Market?

The growth rate of the Active Pharmaceutical Ingredients CDMO Market is 6.7%, with an estimated value of $136.1 billion by 2028.

What is the forecasted size of the Active Pharmaceutical Ingredients CDMO Market?

The Active Pharmaceutical Ingredients CDMO Market is estimated to be worth $136.1 billion by 2028.

Who are the key companies in the Active Pharmaceutical Ingredients CDMO Market?

Key companies in the Active Pharmaceutical Ingredients CDMO Market include Cambrex, ReciPharm, ThermoFisher Pantheon, Corden Pharma., Samsung Biologics, Lonza, Catalent, Siegfried and Boehringer Ingelheim.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Cambrex
  • Catalent
  • Corden Pharma.
  • Lonza
  • Piramal Pharma Solutions

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region Wise Market: Base Estimates
1.6.2 Global Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1: Understanding market dynamics
1.8.2 Objective - 2: Understanding market estimates and forecasts
1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
1.8.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing pharmaceutical R&D investment
3.2.1.2 Rising demand for generic drugs
3.2.1.3 Patent expiration
3.2.1.4 Expanding consumption of biopharmaceuticals
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent government regulations
3.3 Penetration & Growth Prospect Mapping
3.4 COVID-19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 Active Pharmaceutical Ingredient CDMO: Market Analysis Tools
3.6.1 Industry Analysis - Porter’s
3.6.2 PESTEL Analysis
Chapter 4 Active Pharmaceutical Ingredient CDMO Market: Product Segment Analysis
4.1 Active Pharmaceutical Ingredient CDMO Market: Product Market Share Analysis, 2020 & 2028
4.2 Traditional Active Pharmaceutical Ingredient
4.2.1 Traditional Active Pharmaceutical Ingredient Market, 2016 - 2028 (USD Million)
4.3 Highly Potent Active Pharmaceutical Ingredient
4.3.1 Highly Potent Active Pharmaceutical Ingredient Market, 2016 - 2028 (USD Million)
4.4 Antibody Drug Conjugate
4.4.1 Antibody Drug Conjugate Market, 2016 - 2028 (USD Million)
4.5 Others
4.5.1 Others, 2016 - 2028 (USD Million)
Chapter 5 Active Pharmaceutical Ingredient CDMO Market: Synthesis Segment Analysis
5.1 Active Pharmaceutical Ingredient CDMO Market: Synthesis Market Share Analysis, 2020 & 2028
5.2 Synthetic
5.2.1 Synthetic Active Pharmaceutical Ingredient CDMO market, 2016 - 2028 (USD Million)
5.3 Biotech
5.3.1 Biotech Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
Chapter 6 Active Pharmaceutical Ingredient CDMO Market: Drug Segment Analysis
6.1 Active Pharmaceutical Ingredient CDMO Market: Drug Market Share Analysis, 2020 & 2028
6.2 Innovative
6.2.1 Innovative active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
6.3 Generics
6.3.1 Generics Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
Chapter 7 Active Pharmaceutical Ingredient CDMO Market: Application Segment Analysis
7.1 Active Pharmaceutical Ingredient CDMO Market: Application Market Share Analysis, 2020 & 2028
7.2 Oncology
7.2.1 Oncology Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
7.3 Hormonal
7.3.1. Hormonal Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
7.4 Glaucoma
7.4.1. Glaucoma Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
7.5 Cardiovascular
7.5.1. Cardiovascular Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
7.6 Diabetes
7.6.1. Diabetes Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
7.7 Others
7.7.1. Others Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
Chapter 8 Active Pharmaceutical Ingredient CDMO Market: Work Flow Segment Analysis
8.1 Active Pharmaceutical Ingredient CDMO Market: Workflow Market Share Analysis, 2020 & 2028
8.2 Clinical
8.2.1 Clinical Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
8.3 Commerical
8.3.1 Commerical Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
Chapter 9 Active Pharmaceutical Ingredient CDMO Market: Regional Analysis
9.1 Active Pharmaceutical Ingredient CDMO Market: Regional Market Share Analysis, 2020 & 2028
9.2 North America
9.2.1 North America Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.2.2 U.S.
9.2.2.1 U.S. Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.2.3 Canada
9.2.3.1 Canada Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.3 Europe
9.3.1 Europe Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.3.2 U.K.
9.3.2.1 U.K. Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.3.3 Germany
9.3.3.1 Germany Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.3.4 France
9.3.4.1 France Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.3.5 Italy
9.3.5.1 Italy Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.3.6 Spain
9.3.6.1 Spain Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.4.2 Japan
9.4.2.1 Japan Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.4.3 China
9.4.3.1 China Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.4.4 India
9.4.4.1 India Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.4.5 Australia
9.4.5.1 Australia Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.4.6 South Korea
9.4.6.1 South Korea Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.5 Latin America
9.5.1 Latin America Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.5.2 Brazil
9.5.2.1 Brazil Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.5.3 Mexico
9.5.3.1 Mexico Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.5.4 Argentina
9.5.4.1 Argentina Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.5.5 Colombia
9.5.5.1 Colombia Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.5.6 Chile
9.5.6.1 Chile Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.6 MEA
9.6.1 MEA Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.6.2 South Africa
9.6.2.1 South Africa Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.6.3 Saudi Arabia
9.6.3.1 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
9.6.4 UAE
9.6.4.1 UAE Active Pharmaceutical Ingredient CDMO Market, 2016 - 2028 (USD Million)
Chapter 10 Company Profiles
10.1 Cambrex
10.1.1 Company Overview
10.1.2 Service Benchmarking
10.1.3 Financial Performance
10.1.4 Strategic Initiatives
10.2 ReciPharm
10.2.1 Company Overview
10.2.2 Financial Performance
10.2.3 Service Benchmarking
10.2.4 Strategic Initiatives
10.3 ThermoFisher Pantheon
10.3.1 Company Overview
10.3.2 Service Benchmarking
10.3.3 Strategic Initiatives
10.4 Corden Pharma.
10.4.1 Company Overview
10.4.2 Financial Performance
10.4.3 Service Benchmarking
10.5 Samsung Biologics
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Service Benchmarking
10.6 Lonza
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.3 Service Benchmarking
10.7 Catalent
10.7.1 Company Overview
10.7.2 Financial Performance
10.7.3 Service Benchmarking
10.7.4 Strategic Initiatives
10.8 Siegfried
10.8.1 Company Overview
10.8.2 Financial Performance
10.8.3 Service Benchmarking
10.9 Piramal Pharma Solutions
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Service Benchmarking
10.9.4 Strategic Initiatives
10.10 Boehringer Ingelheim
10.10.1 Company Overview
10.10.2 Financial Performance
10.10.3 Service Benchmarking
10.10.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Active Pharmaceutical Ingredient CDMO Market, by Region, 2016 - 2028 (USD Million)
Table 4 Global Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 5 Global Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 6 Global Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 7 Global Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 8 Global Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 9 North America Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
Table 10 North America Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 11 North America Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 12 North America Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 13 North America Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 14 North America Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 15 U.S. Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 16 U.S. Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 17 U.S. Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 18 U.S. Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 19 U.S. Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 20 Canada Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 21 Canada Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 22 Canada Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 23 Canada Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 24 Canada Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 25 Europe Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
Table 26 Europe Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 27 Europe Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 28 Europe Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 29 Europe Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 30 Europe Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 31 U.K. Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 32 U.K. Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 33 U.K. Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 34 U.K. Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 35 U.K. Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 36 Germany Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 37 Germany Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 38 Germany Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 39 Germany Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 40 Germany Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 41 France Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 42 France Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 43 France Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 44 France Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 45 France Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 46 Italy Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 47 Italy Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 48 Italy Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 49 Italy Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 50 Italy Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 51 Spain Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 52 Spain Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 53 Spain Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 54 Spain Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 55 Spain Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 56 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
Table 57 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 58 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 59 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 60 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 61 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 62 India Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 63 India Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 64 India Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 65 India Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 66 India Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 67 Japan Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 68 Japan Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 69 Japan Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 70 Japan Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 71 Japan Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 72 China Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 73 China Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 74 China Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 75 China Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 76 China Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 77 Australia Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 78 Australia Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 79 Australia Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 80 Australia Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 81 Australia Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 82 South Korea Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 83 South Korea Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 84 South Korea Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 85 South Korea Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 86 South Korea Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 87 Latin America Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
Table 88 Latin America Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 89 Latin America Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 90 Latin America Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 91 Latin America Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 92 Latin America Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 93 Brazil Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 94 Brazil Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 95 Brazil Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 96 Brazil Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 97 Brazil Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 98 Mexico Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 99 Mexico Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 100 Mexico Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 101 Mexico Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 102 Mexico Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 103 Argentina Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 104 Argentina Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 105 Argentina Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 106 Argentina Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 107 Argentina Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 108 Colombia Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 109 Colombia Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 110 Colombia Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 111 Colombia Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 112 Colombia Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 113 Chile Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 114 Chile Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 115 Chile Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 116 Chile Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 117 Chile Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 118 MEA Active Pharmaceutical Ingredient CDMO Market, by Country, 2016 - 2028 (USD Million)
Table 119 MEA Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 120 MEA Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 121 MEA Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 122 MEA Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 123 MEA Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 124 South Africa Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 125 South Africa Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 126 South Africa Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 127 South Africa Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 128 South Africa Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 129 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 130 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 131 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 132 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 133 South Arabia Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
Table 134 UAE Active Pharmaceutical Ingredient CDMO Market, by Product, 2016 - 2028 (USD Million)
Table 135 UAE Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2016 - 2028 (USD Million)
Table 136 UAE Active Pharmaceutical Ingredient CDMO Market, by Drug, 2016 - 2028 (USD Million)
Table 137 UAE Active Pharmaceutical Ingredient CDMO Market, by Application, 2016 - 2028 (USD Million)
Table 138 UAE Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2016 - 2028 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Secondary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Active Pharmaceutical Ingredients CDMO market snapshot (2020)
Fig. 9 Active Pharmaceutical Ingredients CDMO market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Porter’s five forces analysis
Fig. 14 PESTEL analysis
Fig. 15 Active Pharmaceutical Ingredients CDMO market Product outlook: Segment dashboard
Fig. 16 Active Pharmaceutical Ingredients CDMO market: Product movement analysis
Fig. 17 Traditional Active Pharmaceutical Ingredient market, 2016 - 2028 (USD Million)
Fig. 18 Highly Potent Active Pharmaceutical Ingredient market, 2016 - 2028 (USD Million)
Fig. 19 Antibody Drug Conjugate market, 2016 - 2028 (USD Million)
Fig. 20 Others market, 2016 - 2028 (USD Million)
Fig. 21 Active Pharmaceutical Ingredients CDMO market Synthesis outlook: Segment dashboard
Fig. 22 Active Pharmaceutical Ingredients CDMO market: Synthesis movement analysis
Fig. 23 Synthetic based Active Pharmaceutical Ingredients CDMO market, 2016 - 2028 (USD Million)
Fig. 24 Biotech based Active Pharmaceutical Ingredients CDMO market, 2016 - 2028 (USD Million)
Fig. 25 Active Pharmaceutical Ingredients CDMO market Drug outlook: Segment dashboard
Fig. 26 Active Pharmaceutical Ingredients CDMO market: Drug movement analysis
Fig. 27 Innovative based Active Pharmaceutical Ingredients CDMO market, 2016 - 2028 (USD Million)
Fig. 28 Generics based Active Pharmaceutical Ingredients CDMO market, 2016 - 2028 (USD Million)
Fig. 29 Active Pharmaceutical Ingredients CDMO market Application outlook: Segment dashboard
Fig. 30 Active Pharmaceutical Ingredients CDMO market: Application movement analysis
Fig. 31 Oncology market, 2016 - 2028 (USD Million)
Fig. 32 Hormonal market, 2016 - 2028 (USD Million)
Fig. 33 Glaucoma market, 2016 - 2028 (USD Million)
Fig. 34 Cardiovascular market, 2016 - 2028 (USD Million)
Fig. 35 Diabetes market, 2016 - 2028 (USD Million)
Fig. 36 Others market, 2016 - 2028 (USD Million)
Fig. 37 Active Pharmaceutical Ingredients CDMO market Workflow outlook: Segment dashboard
Fig. 38 Active Pharmaceutical Ingredients CDMO market: Workflow movement analysis
Fig. 39 Clinical market, 2016 - 2028 (USD Million)
Fig. 40 Commercial market, 2016 - 2028 (USD Million)
Fig. 41 Regional market: Key takeaways
Fig. 42 Regional outlook, 2020 & 2028
Fig. 43 North America market, 2016 - 2028 (USD Million)
Fig. 44 U.S. market, 2016 - 2028 (USD Million)
Fig. 45 Canada market, 2016 - 2028 (USD Million)
Fig. 46 Europe market, 2016 - 2028 (USD Million)
Fig. 47 U.K. market, 2016 - 2028 (USD Million)
Fig. 48 Germany market, 2016 - 2028 (USD Million)
Fig. 49 France market, 2016 - 2028 (USD Million)
Fig. 50 Italy market, 2016 - 2028 (USD Million)
Fig. 51 Spain market, 2016 - 2028 (USD Million)
Fig. 52 Asia Pacific market, 2016 - 2028 (USD Million)
Fig. 53 Japan market, 2016 - 2028 (USD Million)
Fig. 54 China market, 2016 - 2028 (USD Million)
Fig. 55 India market, 2016 - 2028 (USD Million)
Fig. 56 Australia market, 2016 - 2028 (USD Million)
Fig. 57 South Korea market, 2016 - 2028 (USD Million)
Fig. 58 Latin America market, 2016 - 2028 (USD Million)
Fig. 59 Brazil market, 2016 - 2028 (USD Million)
Fig. 60 Mexico market, 2016 - 2028 (USD Million)
Fig. 61 Argentina market, 2016 - 2028 (USD Million)
Fig. 62 Colombia market, 2016 - 2028 (USD Million)
Fig. 63 Chile market, 2016 - 2028 (USD Million)
Fig. 64 MEA market, 2016 - 2028 (USD Million)
Fig. 65 South Africa market, 2016 - 2028 (USD Million)
Fig. 66 Saudi Arabia market, 2016 - 2028 (USD Million)
Fig. 67 UAE market, 2016 - 2028 (USD Million)
Note: Product cover images may vary from those shown
  • Cambrex
  • ReciPharm
  • ThermoFisher Pantheon
  • Corden Pharma.
  • Samsung Biologics
  • Lonza
  • Catalent
  • Siegfried
  • Piramal Pharma Solutions
  • Boehringer Ingelheim
Note: Product cover images may vary from those shown

Loading
LOADING...